We use cookies to ensure that we give you the best experience on our website Learn more

May 15, 2019

ESOC-2019

THERAPEUTIC GAP IN LIPID-LOWERING THERAPY AND OUTCOMES AFTER STROKE: A STUDY OF 10,231 CHINESE STROKE PATIENTS

;

ischemic stroke

transient ischemic attack

lipid-lowering treatment

12-month outcomes

Abstract

Abstract

thumbnail

Keywords

ischemic stroke

transient ischemic attack

lipid-lowering treatment

12-month outcomes

Abstract

Background: Guidelines recommend intensive low-density-lipoprotein cholesterol (LDL-C) lowering after ischemic stroke (IS). We evaluated “real-world” temporal trend in lipid-lowering treatment (LLT) and outcomes after IS in a Chinese population. Methods: We retrospectively evaluated consecutive patients admitted with IS or transient ischemic attack (TIA) between January 2005 and September 2017 to an academic institution. Temporal trends in lipid profile, LLT and 12-month major adverse cardiovascular and cerebrovascular events (MACCE, including cardiovascular death, myocardial infarction and stroke) were compared between 2005-2008, 2009-2012 and 2013-2017. Multivariate analysis was performed to identify independent outcome predictors. Results: Of 10,231 patients, 95% (n=9,719; mean age 72.1±12.8 years; 52.3% male) survived to hospital discharge (n=3,172 [2005-2008]; n=3,135 [2009-2012]; n=3,412 [2013-2017]). From baseline to month 12, mean LDL-C reduced from 3.0±1.0 to 2.2± 0.8 (2005-2008 and 2009-2012) and 2.7±1 to 2.0±0.7 (2013-2107) (p<0.01). Statin therapy on discharge increased over time from 52.1% to 70.7% and 78.3% (p<0.01). Use of high-intensity statin therapy (1.5%) and proportion of patients who achieved target LDL-C <1.8mmol/L (12.7%) was low. Rates of 12-month IS/TIA decreased over time from 7.7% to 7.1% and 6.2% (p=0.05) and MACCE from 12.5% to 10.9% and 9.3% (p<0.01). Initiation of statin in patients with baseline LDL-C >2.6mmol/L was an independent predictor of lower 12-month MACCE (OR 0.71, 95%CI 0.59-0.85, p<0.01). Conclusions: LLT use after stroke improved over time but remained sub-optimal with significant number of patients not prescribed statins. Use of high-intensity statin and proportion of patients who reached LDL-C goal was very low.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.